Onsite at ESMO 2025, pharmaphorum spoke with Adrian Jubb, head of oncology and neurology clinical development at Corcept, and ...

Ipsen has reached an agreement to buy fellow French firm ImCheck Therapeutics in a deal that could be worth up to €1 billion ...

How overwhelming schedules and demanding clinical environments – as well as an increasingly overwhelming amount of ...

Takeda has partnered with China's Innovent Biologics for a pair of late-stage cancer therapies, in a deal that includes an ...

An oversubscribed seed funding round will give Procyon the financial resources it needs to launch its first diagnostic – ...

The company ended the first half of this year with €3.1 billion ($3.6 billion) in cash reserves, and is due to report its ...

Novo Nordisk's chairman Helge Lund and several other independent board members have indicated they will step down next month, ...

However, it was the late-breaking Phase 1/2 data from the SOHO-01 study of sevabertinib (BAY 2927088) in advanced HER2-mutant ...

GSK and Spero Therapeutics' oral cabapenem, tebipenem HBr, has become the first antibiotic in the class to show efficacy in a ...

Hevia and Sousa discuss the landscape of unmet needs in metastatic castration-resistant prostate cancer, what the new data ...

Alex and Schnappauf explain how Vault CRM is a step-change for companies like Bayer, and discuss the benefits of being able ...

Henry Gosebruch, pictured here during his time at Neumora, is replacing Paul Stoffels as CEO of Galapagos. Just a few months after announcing a plan to separate its drug and cell therapy businesses ...